Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
Administration, Metronomic
/ veterinary
Animals
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Chemotherapy, Adjuvant
Cyclophosphamide
/ administration & dosage
Dacarbazine
/ administration & dosage
Dog Diseases
/ drug therapy
Dogs
Doxorubicin
/ administration & dosage
Female
Hemangiosarcoma
/ therapy
Male
Retrospective Studies
Splenic Neoplasms
/ therapy
Treatment Outcome
Vincristine
/ administration & dosage
dog
hemangiosarcoma
maximum tolerated chemotherapy
metastasis
metronomic chemotherapy
prognosis
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
11
02
2019
revised:
23
06
2019
accepted:
24
06
2019
pubmed:
30
6
2019
medline:
7
3
2020
entrez:
29
6
2019
Statut:
ppublish
Résumé
Treatment options for dogs with metastatic (stage III) splenic hemangiosarcoma are limited. A doxorubicin-based chemotherapy regimen is commonly administered; however, there are no published data to support this practice. The aim of this study was to investigate the impact of maximum-tolerated-dose chemotherapy (MTD), metronomic chemotherapy (MC) and no adjuvant treatment on outcome in dogs with stage III splenic hemangiosarcoma undergoing splenectomy. Medical records of dogs with stage III splenic hemangiosarcoma that underwent splenectomy followed by MTD chemotherapy, MC or no adjuvant treatment were retrieved. Time to progression (TTP), survival time (ST) and toxicity were evaluated. One hundred three dogs were identified: 23 received adjuvant MTD, 38 MC and 42 were not medically treated. Overall median TTP and ST were 50 (95% confidence interval [CI], 39-61) and 55 days (95% CI, 43-66), respectively. Dogs treated with adjuvant MTD had a significantly longer TTP and ST compared with dogs receiving MC (median TTP, 134 vs 52 days, P = .025; median ST, 140 vs 58 days, P = .023, respectively). Dogs treated by splenectomy only had the shortest median TTP (28 days) and ST (40 days). However, treatment-related adverse events (AEs) were significantly more frequent in the MTD group (P = .017). The outcome for dogs with metastatic splenic hemangiosarcoma is poor. While MTD showed greater efficacy compared to MC, toxicity was higher in this group. Treatment-related AEs need to be carefully balanced against this modest survival prolongation when offering adjuvant MTD to dogs with advanced stage hemangiosarcoma.
Substances chimiques
Antineoplastic Agents
0
Vincristine
5J49Q6B70F
Dacarbazine
7GR28W0FJI
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
537-544Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Thamm DH. Hemangiosarcoma. In: Withrow SJ, Vali DM, eds. Withrow & MacEwen's Small Animal Clinical Oncology. 5th ed. St Louis, MO: Saunders Elsevier; 2013:679-688.
Lamerato-Kozicki AR, Helm KM, Jubala CM, Cutter GC, Modiano JF. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol. 2006;34:870-878.
Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. J Am Vet Med Assoc. 1985;186:56-58.
Hammond TN, Pesillo-Crosby SA. Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005). J Am Vet Med Assoc. 2008;232:553-558.
Schultheiss PC. A retrospective study of visceral and nonvisceral hemangiosarcoma and hemangiomas in domestic animals. J Vet Diagn Invest. 2004;16:522-526.
Pintar J, Breitschwerdt EB, Hardie EM, Spaulding KA. Acute nontraumatic hemoabdomen in the dog: a retrospective analysis of 39 cases (1987-2001). J Am Anim Hosp Assoc. 2003;39:518-522.
Johnson KA, Powers BE, Withrow SJ, Sheetz MJ, Curtis CR, Wrigley RH. Splenectomy in dogs. Predictors of neoplasia and survival after splenectomy. J Vet Intern Med. 1989;3:160-166.
Waters DJ, Hayden DW, Walter PA. Intracranial lesions in dogs with hemangiosarcoma. J Vet Intern Med. 1989;3:222-230.
Wendelburg KM, Price LL, Burgess KE, Lyons JA, Lew FH, Berg J. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). J Am Vet Med Assoc. 2015;247:393-403.
Kim SE, Liptac JM, Gall TT, Monteith GJ, Woods JP. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004). J Am Vet Med Assoc. 2007;231:1550-1557.
Sorenmo KU, Baez JL, Clifford CA, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med. 2004;18:209-223.
Matsuyama A, Poirier VJ, Mantovani F, Foster RA, Mutsaers AJ. Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic Hemangiosarcoma. J Am Anim Hosp Assoc. 2017;53:304-312.
Sorenmo K, Samluk M, Clifford C, et al. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. J Vet Intern Med. 2007;21:1347-1354.
Finotello R, Stefanello D, Zini E, Marconato L. Comparison of doxorubicin with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. Vet Comp Oncol. 2017;15:25-35.
Hammer AS, Couto CG, Filppi J, Getzy D, Shank K. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicine, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med. 1991;5:160-166.
Alvarez FJ, Hosoya K, Lara-Garcia A, Kisseberth W, Couto G. VAC protocol for treatment of dogs with stage III hemangiosarcoma. J Am Anim Hosp Assoc. 2013;49:370-377.
Leach TN, Childress MO, Greene SN, et al. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. Vet Comp Oncol. 2011;10:102-112.
Schrempp DR, Childress MO, Stewart JC, et al. Metronomic administration of chlorambucil for treatment of digs with urinary bladder transitional call carcinoma. J Am Vet Med Assoc. 2013;242:1534-1538.
Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and Piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med. 2008;22:1373-1379.
Tripp CD, Fidel J, Anderson CL, et al. Tolerability of metronomic administration of Lomustine in dogs with cancer. J Vet Intern Med. 2011;25:278-284.
Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014;5:186-192.
Madondo M, Quinn M, Plebanski M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat Rev. 2017;42:3-9.
Gaspar TB, Henriques J, Marconato L, Queiroga FL. The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field. Vet Comp Oncol. 2018;16:2-11.
Lana S, U'ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med. 2007;21:764-769.
Veterinary Co-operative Oncology Group. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy for biological antineoplastic therapy in dogs and cats. Vet Comp Oncol. 2004;2:195-231.
Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol. 2013;13:176-183.
Finotello R, Henriques J, Sabattini S, et al. A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine hemangiosarcoma. Vet Comp Oncol. 2017;15:493-503.
Alexander CK, Cronin KL, Silver M, Gardner HL, London C. The addition of metronomic chemotherapy does not improve outcome for canine splenic hemangiosarcoma. J Small Anim Pract. 2018;60:32-37.
Bray JP, Orbell G, Cave N, Munday JS. Does thalidomide prolong survival in dogs with splenic haemangiosarcoma? J Small Anim Pract. 2018;59:85-91.
Piccart-Gebhart MJ. Mathematics and oncology: a match for life? J Clin Oncol. 2003;21:1425-1428.
Kerbek RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:426-436.
Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342-4346.